The Platinum Healthcare LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
Here's the summary: On October 1, 2026, the FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter to The Platinum Healthcare LLC (CEO Jamey Hagan) regarding unapproved new drugs "Sycosis" and "Syphillinum" marketed on the company's website for treatment of sexually transmitted infections. The products lack FDA approval required under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act, and the agency states that unapproved OTC products for STI treatment pose serious public health risks including potential for severe complications and disease transmission. The company was directed to respond within 15 business days with corrective actions.
Argus analysis
# FDA Warning Letter Analysis: The Platinum Healthcare LLC
**Company and Violations**
The Platinum Healthcare LLC, a Tennessee-based firm led by CEO Jamey Hagan, received a warning letter from the FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026. The agency identified two products—"Sycosis" and "Syphillinum"—marketed through the company's website as unapproved new drugs. Both products are labeled as homeopathic oral antigens intended to address immune responses related to gonorrhea and syphilis, respectively. The FDA characterized these offerings as presenting a serious public health threat because consumers relying on them may delay appropriate medical treatment for sexually transmitted infections, risking severe complications including infertility, sepsis, and death.
**Regulatory Citations**
The violations center on sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d) and 355(a)), which prohibit the introduction or delivery of unapproved new drugs into interstate commerce. Section 201(g)(1) (21 U.S.C. 321(g)(1)) defines drugs as articles intended to affect disease or bodily function. The warning letter emphasizes that homeopathic products are subject to identical approval requirements as conventional drugs—no exemption exists under federal law. Products must demonstrate they are generally recognized as safe and effective (GRASE) or obtain FDA approval through section 505 applications. No such approvals were in effect for these products.
**Response Timeline and Industry Outlook**
The Platinum Healthcare LLC must submit a written response within fifteen business days, detailing corrective actions, root cause analysis, and preventative measures. Compliance officers in the homeopathic and dietary supplement sector should monitor whether the company ceases product sales, modifies labeling claims, or pursues formal drug approval pathways. The FDA's statement that this list is "not all-inclusive" suggests potential expanded scrutiny of the company's other products. Continued non-compliance may result in seizure or injunction proceedings.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER The Platinum Healthcare LLC MARCS-CMS 735147 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Jamey Hagan Recipient Title CEO The Platinum Healthcare LLC 1019 N 1st Street Pulaski , TN 38478 United States office@platinumwellnesscenter.org Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 735147 To Jamey Hagan: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://platinumwellnesscenter.org/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “Sycosis” and “Syphillinum” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://platinumwellnesscenter.org/ in July 2026. Based on our review, “Sycosis” and “Syphillinum” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the public from unsafe, ineffective, and poor-quality drugs. Violations of the Federal Food, Drug, and Cosmetic Act The following are violations identified during our review. As a reminde…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has The Platinum Healthcare LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for The Platinum Healthcare LLC as of 2026-10-06. Argus ingests new FDA enforcement records daily.
- What FDA violations was The Platinum Healthcare LLC cited for?
- The FDA Warning Letter to The Platinum Healthcare LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
- When did FDA issue the warning letter to The Platinum Healthcare LLC?
- FDA issued the letter (MARCS-CMS 735147) on 2026-10-01 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to The Platinum Healthcare LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/platinum-healthcare-llc-735147-10012026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). The Platinum Healthcare LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-the-platinum-healthcare-llc-2026-10-01-unapproved-drug
"The Platinum Healthcare LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-the-platinum-healthcare-llc-2026-10-01-unapproved-drug.
Argus HQ Research. "The Platinum Healthcare LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-the-platinum-healthcare-llc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_the_platinum_healthcare_llc_2026_10_01_unapproved_drug_2026,
title = {The Platinum Healthcare LLC — FDA Warning Letter, 2026-10-01: Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-the-platinum-healthcare-llc-2026-10-01-unapproved-drug},
note = {Accessed: October 7, 2026}
}